sarepta therapeutics elevidys

News

Sarepta will resume gene therapy shipments

Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

Sarepta Therapeutics said on Monday it will resume shipping of its gene therapy Elevidys to patients with a rare muscular disorder who can walk, after the FDA recommended the removal of a voluntary hold that was placed on the therapy.

· 4h

FDA allows Sarepta to resume some Elevidys shipments

· 26m · on MSN

Sarepta will resume gene therapy shipments after FDA review of recent patient death

12hon MSN

Sarepta rises 2%; Barclays downgrades to underweight on liquidity and Elevidys concerns

Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...

Sarepta Therapeutics to Lift Pause on Shipments of Duchenne Treatment Elevidys

Sarepta Therapeutics said the Food and Drug Administration informed the company it can lift a voluntary pause on shipments of Elevidys for ambulatory patients with Duchenne. The company said Monday ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Sarepta will resume gene therapy shipments

Trending now